Causes and consequences of methamphetamine and MDMA toxicity

AAPS Journal

Volumn 8, Issue 2, 2006, Pages

  Quinton, Maria S ^a   Yamamoto, Bryan K ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier; Excitotoxicity; Glutamate; Mitochondrial dysfunction; Oxidative stress; Substituted amphetamines

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMINE OXIDASE (FLAVIN CONTAINING); AMPA RECEPTOR ANTAGONIST; ASCORBIC ACID; BICUCULLINE; DIZOCILPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FREE RADICAL; GLUTAMIC ACID; HALOPERIDOL; METABOTROPIC RECEPTOR; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE; QUINPIROLE; RACLOPRIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNINDEXED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2;

CELL LOSS; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DOPAMINERGIC SYSTEM; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG OVERDOSE; ENZYME INHIBITION; EXCITOTOXICITY; HUMAN; LIPID PEROXIDATION; LONG TERM POTENTIATION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECEPTOR BLOCKING; REVIEW;

BLOOD-BRAIN BARRIER; DOPAMINE; HUMANS; METHAMPHETAMINE; MITOCHONDRIA; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXINS; OXIDATIVE STRESS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 33646920890     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080238     Document Type: Review

References (100)

1. Hotchkiss AJ, Morgan ME, Gibb JW. The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci. 1979;25:1373-1378.
2. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 1980;181:151-160.
3. Ricaurte GA, Schuster CR, Seiden LS. Long-term effects of repeated methylamphetamine administration on dopamine and scrotonin neurons in the rat brain: a regional study. Brain Res. 1980;193:153-163.
4. Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse. 1994;17:203-209.
5. Raiteri M, Cerrito F, Cervoni AM, Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther. 1979;208:195-202.
6. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res. 1990;26:428435.
7. Nash JF, Yamamoto BK. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 1992;581:237-243.
8. Mark KA, Soghomonian JJ, Yamamoto BK. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci. 2004;24:11449-11456.
9. Yamamoto BK, Gudelsky G, Stephans SE. Amphetamine neurotoxicity: Roles for dopamine, glutamate and oxidative stress. In: Progress in HPLC-HPCE. Utrecht, The Netherlands: VSP; 1998:223-244.
10. Rocher C, Gardier AM. Effects of repeated systemic administration of d-fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:422-428.
11. Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther. 2003;99:45-53.
12. Brown JM, Quinton MS, Yamamoto BK. Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite. J Neurochem. 2005;95:429-436.
13. Hotchkiss AJ, Gibb JW. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther. 1980;214:257-262.
14. Schmidt CJ, Taylor VL. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol. 1987;36:4095-4102.
15. Eisch AJ, Marshall JF. Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse. 1998;30:433-445.
16. Seiden LS, Fischman MW, Schuster CR. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1976;1:215-219.
17. Finnegan KT, Ricaurte G, Seiden LS, Schuster CR. Altered sensitivity to d-methylamphetamine, apomorphine, and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methylamphetamine. Psychopharmacology (Berl). 1982;77:43-52.
18. Green AR, De Souza RJ, Williams JL, Murray TK, Cross AJ. The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole. Neuropharmacology. 1992;31:315-321.
19. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 1989;486:73-78.
20. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 1998;18:8417-8422.
21. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, de Souza EB. 3,4-Methylenedioxymethaphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther. 1987;242:911-916.
22. O'Hearn E, Battaglia G, de Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 1988;8:2788-2803.
23. Finnegan KT, Ricaurte GA, Ritchie LD, Irwin I, Peroutka, SJ, Langston JW. Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res. 1988;447:141-144.
24. Ricaurte GA, Forno LS, Wilson MA. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 1988;260:51-55.
25. Steele TD, McCann LTD, Ricaurte GA. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction. 1994;89:539-551.
26. McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacolgy. 1994;10:129-138.
27. Malberg JE, Sabol KE, Seiden LS. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther. 1996;278:258-267.
28. Fleckenstein AE, Wilkins DG, Gibb JW, Hanson GR. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther. 1997;283:281-285.
29. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 1982;235:93-103.
30. Eisch AJ, Schmued LC, Marshall JF. Characterizing cortical neuron injury with fluoro-jade labeling after a neurotoxic regimen of methamphetamine. Synapse. 1998;30:329-333.
31. O'Dell SJ, Marshall JF. Neurotoxic regimens of methamphetamine induce persistent expression of phospho-c-Jun in somatosensory cortex and substantia nigra. Synapse. 2005;55:137-147.
32. O'Callaghan JP, Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf. 2005;4:433-442.
33. Pu C, Fisher JE, Cappon GD, Vorhees CV. The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum. Brain Res. 1994;649:217-224.
34. Miller DB, O'Callaghan JP. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther. 1994;270:752-760.
35. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther. 1987;241:338-345.
36. Stone DM, Johnson M, Hanson GR, Gibb JW. Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. Eur J Pharmacol. 1989;172:93-97.
37. Gibb JW, Johnson M, Hanson GR. Neurochemical basis of neurotoxicity.Neurotoxicology. 1990;11:317-321.
38. Wagner GC, Carelli RM, Jarvis MF. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology. 1986;25:559-561.
39. Gudelsky GA. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethaphetamine-induced depletion of brain serotonin. J Neural Transm. 1996;103:1397-1404.
40. Colado MI, Green AR. The spin trap reagent alpha-phenlyl-N-tert-butyl nitrone prevents "ecstasy"-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol. 1995;280:343-346.
41. Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. 2004;1016:90-95.
42. Stone DM, Johnson M, Hanson GR, Gibb JW. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther. 1988;247:79-87.
43. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther. 1985;233:539-544.
44. Gudelsky GA, Nash JF. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonindopamine interactions. J Neurochem. 1996;66:243-249.
45. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev. 2003;55:463-508.
46. Marek GJ, Vosmer G, Seiden LS. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res. 1990;513:274-279.
47. Sprague JE, Everman SL, Nichols DE. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology. 1998; 19:427-441.
48. Breier JM, Bankson MG, Yamamoto BK. L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions. J Neurosci. 2006;26:290-299.
49. Bai F, Jones DC, Lau SS, Monks TJ. Serotonergic neurotoxicity of 3,4-(+/ -)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem Res Toxicol. 2001;14:863-870.
50. Jones DC, Lau SS, Monks TJ. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J Pharmacol Exp Ther. 2004;311:298-306.
51. Jiang XR, Wrona MZ, Alguindigue SS, Dryhurst G. Reactions of the putative neurotoxin tryptamine-4,5-dione with L-cysteine and other thiols. Chem Res Toxicol. 2004;17:357-369.
52. Colado MI, O'Shea E, Granados R, Murray TK, Green AR. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol. 1997;121:889-900.
53. Shankaran M, Yamamoto BK, Gudelsky GA. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol. 1999;385:103-110.
54. Shankaran M, Yamamoto BK, Gudelsky GA. Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J Neurochem. 1999;72:2516-2522.
55. Giovanni A, Liang LP, Hastings TG, Zigmond MJ. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J Neurochem. 1995;64:1819-1825.
56. Imam SZ, el Yazal J, Newport GD, et al. Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann N Y Acad Sci. 2001;939:366-380.
57. Shankaran M, Yamamoto BK, Gudelsky GA. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse. 2001;40:55-64.
58. Sprague JE, Nichols DE. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther. 1995;273:667-673.
59. Yamamoto BK, Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther. 1998;287:107-114.
60. Acikgoz O, Gonenc S, Kayatekin BM, et al. Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum. Brain Res. 1998;813:200-202.
61. Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, Sonsalla PK. Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem. 2001;79:152-160.
62. Itzhak Y, Ali SF. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem. 1996;67:1770-1773.
63. Colado MI, Camarero J, Mechan AO, et al. A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MIDMA, 'ecstasy') on dopamine neurones in mouse brain. Br J Pharmacol. 2001;134:1711-1723.
64. Darvesh AS, Yamamoto BK, Gudelsky GA. Evidence for the involvement of nitric oxide in 3,4-methylenedioxymediamphetamine-induced serotonin depletion in the rat brain. J Pharmacol Exp Ther. 2005;312:694-701.
65. Kuhn DM, Sadidi M, Liu X. Peroxynitrite-induced nitration of tyrosine hydroxylase: identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis. J Biol Chem. 2002;277:14336-14342.
66. Sattler R, Tymianski M. Molecular mechanisms of calcium-dependent excitotoxicity. J Mol Med. 2000;78:3-13.
67. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613-622.
68. Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 1989;243:398-400.
69. Finnegan KT, Taraska T. Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo. J Neurochem. 1996;66:1949-1958.
70. Albers DS, Sonsalla PK. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther. 1995;275:1104-1114.
71. Battaglia G, Fornai F, Busceti CL, et al. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci. 2002;22:2135-2141.
72. Burrows KB, Meshul CK. Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex. Synapse. 1997;27:133-144.
73. Mark KA, Eyerman DJ, Yamamoto BK. The Effects of Methamphetamine on the Vesicular Glutamate Transporter 1. Program No. 681.18.2005 Abstract Viewer/Itinerary Planner. 2005; Available at: http://sfn.scholarone.com/itin2005/main.html?new_page_id= 126&abstract_id=16249&p_num=681.18&is-tech=0. Accessed November 15, 2005.
74. Siman R, Noszek JC, Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci. 1989;9:1579-1590.
75. Minger SL, Geddes JW, Holtz ML, et al. Glutamate receptor antagonists inhibit calpain-mediated cytoskeletal proteolysis in focal cerebral ischemia. Brain Res. 1998;810:181-199.
76. Staszewski RD, Yamamoto BK. Methamphetamine-induced spectrin proteolysis in the rat striatum. J Neurochem. 2006;96:1267-1276.
77. Schmidt HH, Hofmann H, Schindler U, Shutenko ZS, Cunningham DD, Feelisch M. No NO from NO synthase. Proc Natl Acad Sci USA. 1996;93:14492-14497.
78. Kahlert S, Zundorf G, Reiser G. Glutamate-mediated influx of extracellular Ca2+ is coupled with reactive oxygen species generation in cultured hippocampal neurons but not in astrocytes. J Neurosci Res. 2005;79:262-271.
79. Chan P, Di Monte DA, Luo JJ, DeLanney LE, Irwin I, Langston JW. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J Neurochem. 1994;62:2484-2487.
80. Nixdorf WL, Burrows KB, Gudelsky GA, Yamamoto BK. Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J Neurochem. 2001;77:647-654.
81. Albers DS, Zeevalk GD, Sonsalla PK. Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP. Brain Res. 1996;718:217-220.
82. Burrows KB, Nixdorf WL, Yamamoto BK. Central administration of mediamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. J Pharmacol Exp Ther. 2000;292:853-860.
83. Stephans SE, Whittingham, TS, Douglas AJ, Lust WD, Yamamoto BK. Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum. J Neurochem. 1998;71:613-621.
84. Wan FJ, Lin HC, Kang BH, Tseng CJ, Tung CS. D-amphetamine-induced depletion of energy and dopamine in the rat striatum is attenuated by nicotinamide pretreatment. Brain Res Bull. 1999;50:167-171.
85. Zeevalk GD, Derr-Yellin E, Nicklas WJ. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J Pharmacol Exp Ther. 1995;275:1124-1130.
86. Darvesh AS, Shankaran M, Gudelsky GA.3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. J Pharmacol Exp Ther. 2002;301:138-144.
87. Burrows KB, Gudelsky G, Yamamoto BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J Pharmacol. 2000;398:11-18.
88. Kushnareva YE, Wiley SE, Ward MW, Andreyev AY, Murphy AN. Excitotoxic injury to mitochondria isolated from cultured neurons. J Biol Chem. 2005;280:28894-28902.
89. Brown JM, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem. 2000;74:2221-2223.
90. Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol. 2002; 449:71-74.
91. Eyerman DJ, Yamamoto BK. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J Pharmacol Exp Ther. 2005;312:160-169.
92. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci. 2002;22:8951-8960.
93. Eyerman DJ, Yamamoto BK. A Rapid and Long-lasting Decrease in Vesicular Monoamine Transporter 2 Immunoreactivity in Striatal Synaptosomes After Methamphetamine. Program No. 981.17.2005. Abstract Viewer/Itinerary Planner 2005; Available at: http://sfn.scholarone.com/itin2005/main.html?new_page_id= 126&abstract_id=17188&p_num=918.17&is_tech=0. Accessed April 27, 2006.
94. Hatzipetros T, Yamamoto BK. Dopaminergic and GABAergic modulation of glutamate release from subthalamic nucleus efferents to the rat substantia nigra. Brain Res. 2006; 1076:60-67.
95. Bustamante D, You ZB, Castel MN, et al. Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat J Neurochem. 2002;83:645-654.
96. Hatzipetros T, Yamamoto BK. Methamphetamine-induced Spectrin Proteolysis and Dopamine Depletions in the Substantia Nigra. Program No. 563.15.2004. Abstract Viewer/Itinerary Planner. 2004; Available at: http://sfn.scholarone.com/itin2004/main.html?new_page_id= 126&abstract_id=10146&p_num-563.15&is_tech=0. Accessed April 27, 2006.
97. Hatzipetros T, Yamamoto BK. The Effects of Haloperidol Treatment After Methamphetamine On the Neuronal Population of the Rat Substantia Nigra. Program No. 918.5.2005. Abstract Viewer/Itinerary Planner. 2005; Available at: http://sfn.scholarone.com/itin2005/main.html?new_page_id= 126&abstract_id=3411&p_num=9l8.5&is_tech=0. Accessed April 27, 2006.
98. Stanimirovic DB, Wong J, Ball R, Durkin JP. Free radical-induced endothelial membrane dysfunction at the site of blood-brain barrier: relationship between lipid peroxidation, Na,K-ATPase activity, and 51Cr release. Neurochem Res. 1995;20:1417-1427.
99. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173-185.
100. Bankson MG, Yamamoto BK. MDMA Causes Long-term Increases in Blood Brain Barrier Permeability. Program No. 190.4.2005 Abstract Viewer/Itinerary Planner 2005; Available at: http://sfh.scholarone.com/itin2005/main.html?new_page_id= 126&abstract_id=15187&p_num=190.4&is-tech=0. Accessed April 27, 2006.